{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-149021","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.691246+00:00","generated_at":"2026-05-15T06:47:49.091861+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Quince Therapeutics announces 1-for-10 reverse stock split effective April 10, 2026","bullets":["Approximately 16.3M shares outstanding post-split; ratio 1-for-10.","Certificate of Amendment filed with Delaware on April 9; effective 11:59 PM ET April 10.","Split-adjusted trading on Nasdaq begins at market open April 13; new CUSIP 22053A206.","Stock options and warrants proportionally adjusted; no change to rights or preferences.","Equiniti Trust Company appointed as exchange agent; fractional shares paid in cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-149021","json":"https://secwatch.observer/filing/0001193125-26-149021.json","markdown":"https://secwatch.observer/filing/0001193125-26-149021.md","text":"https://secwatch.observer/filing/0001193125-26-149021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526149021/0001193125-26-149021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526149021/d115661d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:47:49.091861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b19128e0e87ab0a36bf462ae77a8219b466d1ed","claim":"Quince Therapeutics, Inc. issued common stock.","evidence_excerpt":"every ten (10) shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one (1) issued and outstanding share of common stock","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526149021/0001193125-26-149021-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"}],"fact_type":"equity_issuance"},{"claim_id":"5a1ddbae434d83cfd2239f4ff641274a9163b400","claim":"Quince Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock, effective April 10, 2026 (effective 2026-04-10).","evidence_excerpt":"on April 9, 2026, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware, which will be effective at 11:59 pm Eastern Time on April 10, 2026.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526149021/0001193125-26-149021-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-04-10"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}